For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the emergence of Tafamidis and Attruby represents a significant breakthrough . These groundbreaking therapies protect the transthyretin protein, preventing its damaging build-up and alleviating the severity of the illness. Individuals are now report